The company manufactures generic products and specialty drugs for gastro-intestinal diseases, with a focus on inflammatory bowel diseases like ulcerative colitis and Crohn's Disease. Their clinical development pipeline includes products for colon disorders, ulcerative colitis, travelers' diarrhea, and anticoagulant treatment. They also have preclinical projects for preventing opioid-induced constipation, colon cancer, and other conditions. Cosmo Pharmaceuticals aims to reduce the incidence of colorectal cancer by improving the detection rate of pre-cancerous lesions during colonoscopy. They also engage in manufacturing products for third parties and have a growing portfolio of specialty products.